Phase 2 HER2-positive Breast Cancer trials recruiting now

All HER2-positive Breast Cancer trials, every phase

Other phases for HER2-positive Breast Cancer

Phase 2 HER2-positive Breast Cancer trials

• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
  NCT07102381 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
  NCT06891833 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 30 locations
• A Study of Surgery and Radiotherapy in People With Breast Cancer
  NCT07053085 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
  NCT06348134 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 4 locations
• BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
  NCT06441890 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Basket Study for Oligo-metastatic Breast Cancer
  NCT05982678 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
  NCT04993014 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
  NCT05918328 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: Female · 1 location
• Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
  NCT06276868 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
  NCT06450314 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
  NCT07486089 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
  NCT07510802 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
  NCT07708194 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients
  NCT07233499 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: Female · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
  NCT07459673 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  NCT01042379 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
  NCT06832904 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
  NCT05306041 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
  NCT07635342 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: Female · 1 location
• Pyrotinib in Women With High-risk in Early Stage Breast Cancer
  NCT05834764 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
  NCT07413939 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 186 locations
• Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
  NCT04899908 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
  NCT05325632 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Screening Brain MRIs in Stage IV Breast Cancer
  NCT05115474 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• TRUDI: TDXD+Durva in HER2+/Low IBC
  NCT05795101 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 3 locations
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations
• Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
  NCT04481932 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
  NCT07647263 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
  NCT04886531 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
  NCT05955170 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
  NCT06016387 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.